The Israeli-made BriLife vaccine is a live virus vaccine, and it may be the key to defeating new variants.
The governmental Israel Institute for Biological Research (IIBR) has signed a memorandum of understanding with NRx Pharmaceuticals to complete the clinical trials of its coronavirus vaccine.
While still deep into clinical trials, the vaccine has already shown promising results in its ability to ward off variants that seem to be bypassing the Pfizer and Moderna inoculations.
Watch and learn about the vaccine’s development, the recent deal, and why the BriLife vaccine may be the key to defeating the concerning variants.